<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PENTAZOCINE HYDROCHLORIDE<img border="0" src="../images/pr.gif"/></span><br/>(pen-taz'oh-seen)<br/><span class="topboxtradename">Talwin<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">narcotic (opiate) agonist-antagonist</span>; <span class="classification">analgesic</span><br/><b>Pregnancy Category: </b>C<br/><b>Controlled Substance: </b>Schedule IV<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>30 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic analgesic with analgesic potency approximately one third that of morphine and somewhat greater than codeine. In
         general, adverse reactions are qualitatively similar to those of morphine. Unlike morphine, large doses may increase BP and
         heart rate.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective for moderate to severe pain relief. Acts as weak narcotic antagonist and has sedative properties.</p>
<h1><a name="uses">Uses</a></h1>
<p>Relief of moderate to severe pain; also used for preoperative analgesia or sedation, and as supplement to surgical anesthesia.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Head injury, increased intracranial pressure; emotionally unstable patients, or history of drug abuse. Safety during pregnancy
         (other than labor) (category C), lactation, or in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired kidney or liver function; respiratory depression; biliary surgery; patients with MI who have nausea and vomiting.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Moderate to Severe Pain (Excluding Patients in Labor)</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 50100 mg q34h (max: 600 mg/d) <span class="rdroute">IM/IV/SC</span> 30 mg q34h (max: 360 mg/d)<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> 50 mg q4h <span class="rdroute">IM</span> 30 mg q4h<br/><br/><span class="indicationtitle">Women in Labor</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 2030 mg; 20 mg may be repeated 1 or 2 times at 23 h intervals<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Subcutaneous/</span><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>IM is preferred to SC route when frequent injections over an extended period are required.</li>
<li>Observe injection sites daily for signs of irritation or inflammation.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted or diluted with 1 mL sterile water for injection for each 5 mg.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give slowly at a rate of 5 mg over 60 sec.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Aminophylline,</b>
<span class="classification">barbiturates</span>, <b>sodium bicarbonate,</b>
<b>glycopyrrolate,</b>
<b>heparin,</b>
<b>nafcillin.</b>
<span class="incompattype">Y-site:</span>
<b>Glycopyrrolate, heparin, nafcillin.</b>
</p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Flushing, allergic reactions, <span class="speceff-life">shock</span>. <span class="typehead">CNS:</span>
<span class="speceff-common">Drowsiness,</span> sweating, <span class="speceff-common">dizziness, light-headedness, euphoria,</span> psychotomimetic effects, confusion, anxiety, hallucinations, disturbed dreams, bizarre thoughts, euphoria and other mood
      alterations. <span class="typehead"> CV:</span> Hypertension, palpitation, tachycardia. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting,</span> constipation, dry mouth, alterations of taste. <span class="typehead">Urogenital:</span> Urinary retention. <span class="typehead">Respiratory:</span>
<span class="speceff-life">Respiratory depression</span>. <span class="typehead">Skin:</span> Injection-site reactions (induration, nodule formation, sloughing, sclerosis, cutaneous depression), rash, pruritus. <span class="typehead">Special Senses:</span> Visual disturbances. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Alcohol</b> and other <span class="classification">cns depressants</span> add to CNS depression; <span class="classification">narcotic analgesics</span> may precipitate narcotic withdrawal syndrome. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract; 20% reaches systemic circulation (first pass metabolism). <span class="typehead">Onset:</span> 1530 min PO, IM, SC; 23 min IV. <span class="typehead">Peak:</span> 13 h PO, IM; 15 min IV. <span class="typehead">Duration:</span> 3 h PO, IM; 1 h IV. <span class="typehead">Distribution:</span> Crosses placenta. <span class="typehead">Metabolism:</span> Extensively metabolized in liver. <span class="typehead">Elimination:</span> Excreted primarily in urine; small amount in feces. <span class="typehead">Half-Life:</span> 23 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor therapeutic effect. Tolerance to analgesic effect sometimes occurs. Psychologic and physical dependence have been
            reported in patients with history of drug abuse, but rarely in patients without such history. Addiction liability matches
            that of codeine.
         </li>
<li>Be aware that pentazocine may produce acute withdrawal symptoms in some patients who have been receiving opioids on a regular
            basis.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Avoid driving and other potentially hazardous activities until response to drug is known.</li>
<li>Do not discontinue drug abruptly following extended use; may result in chills, abdominal and muscle cramps, yawning, runny
            nose, tearing, itching, restlessness, anxiety, drug-seeking behavior.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>